Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Autoimmun ; 117: 102576, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33276307

RESUMEN

In the wide field of nutraceuticals, the effects of mushrooms on immunity, cancer and including autoimmunity have been proposed for centuries but in recent years a growing interest has led scientists to elucidate which specific compounds have bioactive properties and through which mechanisms. Glucans and specific proteins are responsible for most of the biological effects of mushrooms, particularly in terms of immunomodulatory and anti-tumor results. Proteins with bioactive effects include lectins, fungal immunomodulatory proteins (FIPs), ribosome inactivating proteins (RIPs), ribonucleases, laccases, among others. At the present status of knowledge, numerous studies have been performed on cell lines and murine models while only a few clinical trials have been conducted. As in most cases of dietary components, the multitude of variables implicated in the final effect and an inadequate standardization are expected to affect the observed differences, thus making the available evidence insufficient to justify the treatment of human diseases with mushrooms extracts. We will herein provide a comprehensive review and critically discussion the biochemical changes induced by different mushroom compounds as observed in in vitro studies, particularly on macrophages, dendritic cells, T cells, and NK cells, compared to in vivo and human studies. Additional effects are represented by lipids which constitute a minor part of mushrooms but may have a role in reducing serum cholesterol levels or phenols acting as antioxidant and reducing agents. Human studies provide a minority of available data, as well illustrated by a placebo-controlled study of athletes treated with ß-glucan from Pleurotus ostreatus. Variables influencing study outcomes include different mushrooms strains, growing conditions, developmental stage, part of mushroom used, extraction method, and storage conditions. We foresee that future rigorous research will be needed to determine the potential of mushroom compounds for human health to reproduce the effects of some compounds such as lentinan which a metaanalysis demonstrated to increase the efficacy of chemotherapy in the treatment of lung cancer and in the improvement of the patients quality of life.


Asunto(s)
Agaricales , Productos Biológicos , Inmunidad , Agaricales/química , Agaricales/clasificación , Agaricales/metabolismo , Animales , Antineoplásicos/química , Antineoplásicos/farmacología , Autoinmunidad/efectos de los fármacos , Productos Biológicos/química , Productos Biológicos/farmacología , Proteínas en la Dieta/metabolismo , Suplementos Dietéticos , Evaluación del Impacto en la Salud , Humanos , Inmunidad/efectos de los fármacos , Inmunidad Innata/efectos de los fármacos , Inmunomodulación , Leucocitos/efectos de los fármacos , Leucocitos/inmunología , Leucocitos/metabolismo , Activación de Linfocitos/efectos de los fármacos , Activación de Linfocitos/inmunología , beta-Glucanos/metabolismo
2.
J Autoimmun ; 109: 102442, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32253068

RESUMEN

The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2. It shares homology with SARS and MERS-CoV, responsible for past outbreaks in China and in Middle East. SARS-CoV2 spread from China where the first infections were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute respiratory distress syndrome. A cytokine storm has been shown in patients who develop fatal complications, as observed in past coronavirus infections. The management includes ventilatory support and broad-spectrum antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed. Based upon our limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be hypothesized, acting as direct antivirals or targeting host immune response. Antimalarial drugs, commonly used in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have demonstrated efficacy in improving the infection. Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in severe cases and use of tocilizumab has shown good outcomes in a small cohort. Baricitinib has both antiviral and anti-inflammatory properties. Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in the treatment of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should be recommended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing immunosuppressants in case of infection. National and international registries are being created to collect data on rheumatic patients with CoViD-19.


Asunto(s)
Terapia Biológica , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/tratamiento farmacológico , Neumonía Viral/complicaciones , Neumonía Viral/tratamiento farmacológico , Enfermedades Reumáticas/complicaciones , Enfermedades Reumáticas/terapia , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antimaláricos/uso terapéutico , Antirreumáticos/uso terapéutico , Azetidinas/uso terapéutico , Betacoronavirus/efectos de los fármacos , COVID-19 , Infecciones por Coronavirus/prevención & control , Citocinas/inmunología , Humanos , Inmunosupresores/uso terapéutico , Interleucina-1/antagonistas & inhibidores , Interleucina-6/antagonistas & inhibidores , Pandemias/prevención & control , Neumonía Viral/prevención & control , Purinas , Pirazoles , SARS-CoV-2 , Sulfonamidas/uso terapéutico , Internalización del Virus/efectos de los fármacos , Tratamiento Farmacológico de COVID-19
3.
J Autoimmun ; 74: 1-5, 2016 11.
Artículo en Inglés | MEDLINE | ID: mdl-27592380

RESUMEN

The significant decrease in mortality rates worldwide, the increased proportion of patients achieving a durable remission, and the recent approval of a new drug after several decades are encouraging advances in the tangled history of systemic lupus erythematosus (SLE). However, when data are observed more closely, the research findings on disease pathogenesis and targeted treatments have been quite misleading, as illustrated by the central role of B cells but the missed endpoints in rituximab clinical trials which are burdened by the wide variability of SLE manifestations or the ethnic determinants of disease severity. Other biologic therapies, on the other hand, inhibit B cell stimulating factor BAFF but are proving to be short of revolutionary, not yet overcoming high-dose long-term glucocorticoids still largely used without an agreement on what clinical targets are to be sought in the proposed treat-to-target approach. The large amount of data from genome-wide association studies, the detailed reports on T cell epigenetics, or the numerous established and novel animal models have also proven insufficient to change our understanding of the human disease. Nonetheless, we have now tools for a better and earlier SLE diagnosis, thanks to reliable biomarkers, improved care of kidney involvement, better pregnancy outcomes, while the neuropsychiatric manifestations remain challenging. These advances are well mirrored by some proposed synthetic drugs, such as tacrolimus, or biologics, including IFNα inhibitors and other drugs capable to modulate the immune system. Ultimately, we may foresee that genetic and epigenetic data, along with the variable clinical manifestations represent the bases for SLE to become an ideal candidate for the introduction of truly personalized medicine.


Asunto(s)
Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/etiología , Lupus Eritematoso Sistémico/terapia , Medicina de Precisión , Animales , Autoinmunidad , Linfocitos B/inmunología , Linfocitos B/metabolismo , Terapia Biológica/métodos , Biomarcadores , Modelos Animales de Enfermedad , Susceptibilidad a Enfermedades , Epigénesis Genética , Femenino , Estudio de Asociación del Genoma Completo , Humanos , Lupus Eritematoso Sistémico/complicaciones , Masculino , Medicina de Precisión/métodos , Embarazo , Linfocitos T/inmunología , Linfocitos T/metabolismo
4.
Isr Med Assoc J ; 18(3-4): 203-8, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27228644

RESUMEN

Psoriatic arthritis (PsA) is a chronic inflammatory condition associated with skin psoriasis and manifests a wide clinical phenotype, with proposed differences between sexes. Current treatments are based on traditional disease-modifying anti-rheumatic drugs (DMARD), and biologic agents and studies have reported different clinical response patterns depending on sex factors. We aimed to identify sex differences in drug retention rate in patients with PsA and performed a systematic research on MEDLINE, EMBASE and Cochrane databases (1979 to June 2015) for studies regarding effectiveness (measured as drug retention rate) in PsA in both traditional DMARDs and biologics. Demographic data as well as retention rates between sexes were extracted. From a total 709 retrieved references, we included 9 articles for the final analysis. Only one study reported data regarding DMARDs, while eight studies reported retention rate for anti-tumor necrosis factor (TNF) biologics, mainly infliximab, adalimumab and etanercept. No differences were reported in retention rates between sexes for methotrexate, while women manifested lower retention rates compared to men with regard to anti-TNF. We highlight the need to include sex differences in the management flow chart of patients with PsA.


Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Psoriásica/tratamiento farmacológico , Terapia Biológica/métodos , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Resistencia a Medicamentos , Femenino , Humanos , Masculino , Administración del Tratamiento Farmacológico , Metotrexato/uso terapéutico , Factores Sexuales
5.
J Autoimmun ; 65: 64-73, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26330346

RESUMEN

The risk of hematological malignancies is mainly determined by genetic background, age, sex, race and ethnicity, geographic location, exposure to certain chemicals and radiation; along with the more recently proposed immune factors such as chronic inflammation, immunodeficiencies, autoimmunity, and infections. Paradigmatic examples include the development of lymphoma in Sjögren's syndrome and Hashimoto thyroiditis, gastric MALT lymphoma in Helicobacter pylori infection, or lymphomas associated with infections by Epstein-Barr virus, human herpes virus 8 (HHV 8) and leukemia/lymphoma virus 1 (HTLV-1). A growing number of reports indicates an increased risk of lymphoma, particularly of the anaplastic large cell (ALCL) type. The implants, specifically those used in the past, elicit chronic stimulation of the immune system against the prosthetic material. This is particularly the case in genetically susceptible hosts. We suggest that polyclonal activation may result in monoclonality in those at risk hosts, ultimately leading to lymphoma. We suggest that patients with an inflammatory response against silicone implants be monitored carefully.


Asunto(s)
Neoplasias de la Mama/rehabilitación , Inflamación/inducido químicamente , Linfoma Anaplásico de Células Grandes/epidemiología , Linfoma Anaplásico de Células Grandes/etiología , Prótesis e Implantes/efectos adversos , Geles de Silicona/efectos adversos , Autoinmunidad , Implantes de Mama/efectos adversos , Neoplasias de la Mama/cirugía , Desfibriladores Implantables/efectos adversos , Femenino , Infecciones por HTLV-I/complicaciones , Enfermedad de Hashimoto/complicaciones , Infecciones por Helicobacter/complicaciones , Infecciones por Herpesviridae/complicaciones , Humanos , Inflamación/inmunología , Linfoma de Células B de la Zona Marginal/etiología , Linfoma Anaplásico de Células Grandes/clasificación , Linfoma no Hodgkin/complicaciones , Masculino , Prótesis de Pene/efectos adversos , Falla de Prótesis/efectos adversos , Riesgo , Síndrome de Sjögren/complicaciones , Neoplasias Gástricas/complicaciones
6.
Autoimmun Rev ; 14(2): 90-7, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25308531

RESUMEN

Autoimmunity and autoinflammation are generally considered as mutually exclusive mechanisms of diseases but may concur to specific syndromes. Idiopathic recurrent acute pericarditis (IRAP) is defined as the recurrence of pericardial symptoms at any point following the prior cessation of acute pericarditis, and the latency is generally 6 weeks. Manifestations of pericarditis such as pericardial friction rub, electrocardiographic changes, and pericardial effusion are less frequent in the subsequent episodes compared to the index attack, and in some cases the only clinical sign is represented by a suggestive chest pain. Several autoimmune diseases may manifest with pericarditis which is often related to viral infections, while postviral pericarditis may in turn display a nonspecific autoimmune background. Similarly, autoinflammatory syndromes such as familial Mediterranean fever and tumor necrosis factor receptor-associated periodic syndrome are characterized by self-limiting pericardial symptoms. Corticosteroids are generally effective, thus supporting the autoimmune nature of IRAP, but dramatic results are obtained with interleukin-1 blocking agents in corticosteroid-dependent cases, pointing to a pathogenic role for the inflammasome. Based on these observations, we submit that IRAP represents a paradigmatic example of the putative coexistence of autoimmunity and autoinflammation: the main aim of this review is to critically discuss the hypothesis as well as the current understanding of this enigmatic clinical condition.


Asunto(s)
Autoinmunidad , Pericarditis/inmunología , Enfermedad Aguda , Enfermedades Autoinmunes/inmunología , Humanos , Inflamación/inmunología , Recurrencia
7.
Expert Opin Drug Saf ; 14(3): 389-99, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25518908

RESUMEN

INTRODUCTION: The development of biologic therapies has been an enormous leap in the management of patients with rheumatoid and psoriatic arthritis. Since the first anti-TNF-α therapies, numerous molecules have been identified as targets of immunomodulatory therapies, such as IL-1 (anakinra, canakinumab), IL-6 (tocilizumab), CD20(+) B cells (rituximab), CTLA4 (abatacept) and two additional anti-TNF-α therapies (certolizumab pegol, golimumab). AREAS COVERED: In the present review, we will describe the safety issues related to the immunosuppressive action of these biologic drugs that are mainly represented by infection and malignancy. The risk of infection should be identified before initiating a biologic treatment and markers checked over time, in particular for tuberculosis and hepatitis B and C viruses. Other infections (bacterial, viral, parasitic; opportunistic; surgery-related) and safety issues may require temporary interruption of the treatment until complete resolution. No significantly increased risk of malignancy, both hematological and solid, has been associated with the use of biologic agents. In all cases, it is difficult to dissect the risks related to biologics from those related to baseline treatments. EXPERT OPINION: Detailed medical history and laboratory screening should be performed before starting biologic therapies. Clinicians should be aware of the different safety profiles associated with different molecules and they should follow up data coming out of the existing registries for biologics in regard to new or old side effects.


Asunto(s)
Antirreumáticos/efectos adversos , Factores Inmunológicos/efectos adversos , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Antirreumáticos/farmacología , Artritis Psoriásica/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Terapia Biológica/efectos adversos , Terapia Biológica/métodos , Humanos , Factores Inmunológicos/farmacología
8.
Immunol Res ; 61(1-2): 141-6, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25424577

RESUMEN

Vitamin D immune-modulating effects were extensively studied, and low levels have been linked with autoimmune diseases. The associations of vitamin D with autoimmune diseases of the liver, and particularly primary biliary cirrhosis (PBC), are yet to be defined. Hence, in this study, serum levels of vitamin D were determined in 79 patients with PBC and 70 age- and sex-matched controls by the LIAISON chemiluminescent immunoassays (DiaSorin-Italy). Clinical and serological parameters of patients were analyzed with respect to vitamin D status. Mean levels of vitamin D were significantly lower among patients with PBC compared with controls (16.8 ± 9 vs. 22.1 ± 9 ng/ml; p = 0.029), and vitamin D deficiency (≤10 ng/ml) was documented in 33% of patients with PBC versus 7% of controls (p < 0.0001). Vitamin D levels inversely correlated with advanced liver damage and the presence of concomitant autoimmune diseases. In contrast, higher levels of vitamin D were observed among patients with PBC treated with ursodeoxycholic acid (UDCA). In conclusion, low vitamin D levels are common among patients with PBC and correlate with advanced disease, lack of UDCA therapy and autoimmune comorbidity. This alludes to the plausible roles of vitamin D as a prognostic marker of PBC severity, and as a potential player in this disease pathogenesis. While further studies are awaited, monitoring vitamin D in patients with PBC and use of supplements may be advisable.


Asunto(s)
Cirrosis Hepática Biliar/sangre , Cirrosis Hepática Biliar/diagnóstico , Vitamina D/sangre , Anciano , Autoinmunidad , Biomarcadores/sangre , Biopsia , Estudios de Casos y Controles , Femenino , Humanos , Hígado/inmunología , Hígado/patología , Cirrosis Hepática Biliar/etiología , Masculino , Persona de Mediana Edad , Factores de Riesgo , Índice de Severidad de la Enfermedad , Deficiencia de Vitamina D/complicaciones
9.
J Med Food ; 17(3): 374-83, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24588719

RESUMEN

The metabolic syndrome is a major worldwide health care issue and a dominant risk factor for cardiovascular disease. The liver manifestations of this syndrome include nonalcoholic fatty liver disease (NAFLD) and its progressive variant nonalcoholic steatohepatitis (NASH). Although significant research has been performed, the basic pathogenesis of NAFLD/NASH remains controversial and effective treatments are still unavailable. We have previously reported on a murine model of NASH induced by the neonatal injection of monosodium glutamate (MSG), which includes the clinical manifestations of central obesity, diabetes, hyperlipidemia, and ultimately liver inflammation, fibrosis, and cancer. Although MSG is considered a safe food additive, its administration to pregnant rats increases the voracity and growth hormone levels in the offspring. To further understand the biology of this model, we have investigated the influence of the calorie intake on these clinical manifestations by feeding animals a restrictive diet. MSG-treated animals fed a restrictive diet continue to manifest obesity and early stage NASH but have improvements in serum lipid profiles. At 12 months of age, mice had manifestations of obesity, whether animals were fed a restricted or control diet, but animals fed a restrictive diet had a reduction in the progression of NASH. In conclusion, MSG appears to be a critical factor in the initiation of obesity, whereas calorie intake may modulate the progression of disease.


Asunto(s)
Obesidad/dietoterapia , Glutamato de Sodio/efectos adversos , Animales , Dieta Reductora , Progresión de la Enfermedad , Hígado Graso/dietoterapia , Hígado Graso/etiología , Hígado Graso/metabolismo , Hígado Graso/patología , Humanos , Masculino , Ratones Endogámicos ICR , Enfermedad del Hígado Graso no Alcohólico , Obesidad/complicaciones , Obesidad/metabolismo , Glutamato de Sodio/metabolismo
10.
Cell Mol Immunol ; 8(3): 248-54, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21278762

RESUMEN

Anemia and immunological dysfunction (i.e. immunosenescence) are commonly found in older subjects and nutritional approaches are sought to counteract these phenomena. Spirulina is a filamentous and multicellular bule-green alga capable of reducing inflammation and also manifesting antioxidant effects. We hypothesized that Spirulina may ameliorate anemia and immunosenescence in senior citizens with a history of anemia. We enrolled 40 volunteers of both sexes with an age of 50 years or older who had no history of major chronic diseases. Participants took a Spirulina supplementation for 12 weeks and were administered comprehensive dietary questionnaires to determine their nutritional regimen during the study. Complete cell count (CCC) and indoleamine 2,3-dioxygenase (IDO) enzyme activity, as a sign of immune function, were determined at baseline and weeks 6 and 12 of supplementation. Thirty study participants completed the entire study and the data obtained were analyzed. Over the 12-week study period, there was a steady increase in average values of mean corpuscular hemoglobin in subjects of both sexes. In addition, mean corpuscular volume and mean corpuscular hemoglobin concentration also increased in male participants. Older women appeared to benefit more rapidly from Spirulina supplements. Similarly, the majority of subjects manifested increased IDO activity and white blood cell count at 6 and 12 weeks of Spirulina supplementation. Spirulina may ameliorate anemia and immunosenescence in older subjects. We encourage large human studies to determine whether this safe supplement could prove beneficial in randomized clinical trials.


Asunto(s)
Anemia/dietoterapia , Antiinflamatorios/administración & dosificación , Antioxidantes/administración & dosificación , Suplementos Dietéticos , Spirulina , Factores de Edad , Anciano , Anciano de 80 o más Años , Anemia/diagnóstico , Anemia/inmunología , Hemoglobinas/genética , Hemoglobinas/metabolismo , Humanos , Inmunidad/efectos de los fármacos , Indolamina-Pirrol 2,3,-Dioxigenasa/genética , Indolamina-Pirrol 2,3,-Dioxigenasa/metabolismo , Masculino , Persona de Mediana Edad , Spirulina/inmunología
11.
Ann N Y Acad Sci ; 1190: 151-8, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20388146

RESUMEN

The Kampo formula keishibukuryogan (KBG, Guizhifulingwan) is frequently used in traditional Japanese and Chinese medicine to treat several symptoms and manifests anti-inflammatory and scavenging effects. Nonalcoholic fatty liver disease (NAFLD) is a common manifestation of the metabolic syndrome and has the potential to evolve to liver cirrhosis through chronic inflammation and steatohepatisis (NASH). We have recently reported the KBG significant effectiveness on liver injury in a NASH animal model that prompted us to prescribe to KBG (TJ-25). We performed a retrospective study and reviewed the charts of outpatients who were prescribed KBG for 8-12 weeks due to non-liver-related symptoms (n= 11) over the past year to evaluate the clinical outcome. In six of these cases, biochemical and ultrasound signs of NAFLD were observed. KBG led to a significant reduction in liver injury tests and blood cholesterol but had no effects on body weight in all NAFLD cases. Further, liver tests and lipid profiles returned to baseline values when KBG treatment was stopped. On the basis of data on a small number of subjects, we suggest that the use of KBG is a safe complementary treatment in patients with NAFLD. While it is unlikely that Kampo formulas may substitute the current nutritional approaches to the metabolic syndrome, future studies should address the possibility of an additive effect, possibly through anti-inflammatory mechanisms.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Hígado Graso/tratamiento farmacológico , Inflamación/tratamiento farmacológico , Adulto , Hígado Graso/inmunología , Femenino , Humanos , Inflamación/inmunología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del Tratamiento
12.
Autoimmun Rev ; 9(5): A267-70, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19969106

RESUMEN

As well represented by the impaired immune function of malnourished individuals encountered in developing countries and the incidence of specific diseases following local nutrient deficiencies, nutrition and immunity have been linked to each other for centuries while the specific connection between dietary factors and autoimmunity onset or modulation is a more recent acquisition. Autoimmune diseases manifest limited prevalence rates in developing countries while numerous immunity-related claims have been proposed in the field of functional foods. Nevertheless, over the past years multiple lines of evidence have supported a major role for specific dietary factors (including vitamin D, vitamin A, selenium, zinc, omega-3 fatty acids, probiotics, and flavanols) in determining the immune responses involved in infections, allergies, and autoimmune diseases. Interestingly, the link between nutrition and autoimmunity may well contribute to the geoepidemiology observed for numerous conditions. In general terms, most data that will be discussed herein were obtained in experimental or animal models while human data from real-life clinical settings or randomized clinical trials remain largely unsatisfactory. Our current knowledge on the beneficial impact of nutrition on autoimmunity prompts us to encourage the search for evidence-based nutrition to support the everyday diet choices of patients.


Asunto(s)
Autoinmunidad/inmunología , Dieta , Estudios Epidemiológicos , Alimentos Funcionales , Enfermedades Autoinmunes/inmunología , Países en Desarrollo , Ácidos Grasos Omega-3/inmunología , Ácidos Grasos Insaturados , Humanos , Inmunidad/inmunología , Infecciones/inmunología , Masculino , Desnutrición/inmunología , Fenómenos Fisiológicos , Ensayos Clínicos Controlados Aleatorios como Asunto , Vitamina D/inmunología
13.
Clin Rev Allergy Immunol ; 36(2-3): 176-200, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19132559

RESUMEN

Systemic sclerosis (SSc) is a chronic autoimmune disease with clinical manifestations resulting from immune activation, fibrosis development, and damage of small blood vessels. Our aim was to critically illustrate the available data on the new treatments proposed for SSc to provide a clinically oriented overview of the current evidence. PubMed was used for literature search using "scleroderma" and "therapy" to identify all articles published on indexed journals between 1972 and 2008. The search was limited to publications in English and produced a total of 3,441 references, which included 735 review articles. These citations were then screened for articles dealing with the most recent therapy options for SSc, and 214 articles were selected for evaluation and discussion. Methotrexate, cyclophosphamide, calcium channel blockers, angiotensin converting enzyme inhibitors, prostacyclin analogues, D-penicillamine, and extracorporeal photopheresis are the most widely studied treatments for SSc and were considered as practiced treatments. Other therapeutic approaches have been developed more recently and include endothelin receptor antagonists and phosphodiesterase-5 inhibitors for pulmonary arterial hypertension and peripheral vascular disease. High-dose immunosuppression and stem cell transplantation constitute a promising treatment and data from randomized controlled trials are awaited. Intravenous gamma globulins, mycophenolate mophetil, collagen tolerance induction, rituximab, fluoxetine, pirfenidone, relaxin, halofuginone, anti-TGF-beta antibodies, and tyrosine kinase inhibitors awaits more solid data. The clinical management of patients with SSc remains a challenge and currently involves practiced and newly proposed therapeutic approaches. The disease pleiomorphism poses numerous difficulties to determine ideal outcomes to be used in clinical trials.


Asunto(s)
Diferenciación Celular/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Esclerodermia Sistémica/terapia , Transducción de Señal/efectos de los fármacos , Animales , Bloqueadores de los Canales de Calcio/uso terapéutico , Diferenciación Celular/inmunología , Ensayos Clínicos como Asunto , Ciclofosfamida/uso terapéutico , Fibroblastos/inmunología , Fibrosis/tratamiento farmacológico , Humanos , Inmunosupresores/uso terapéutico , Metotrexato/uso terapéutico , Esclerodermia Sistémica/inmunología , Esclerodermia Sistémica/patología , Esclerodermia Sistémica/fisiopatología , Transducción de Señal/inmunología , Vasodilatadores/uso terapéutico , Remodelación Ventricular/efectos de los fármacos
14.
Exp Biol Med (Maywood) ; 233(3): 328-37, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18296738

RESUMEN

Data on the efficacy of herbal compounds are often burdened by the lack of appropriate controls or a limited statistical power. Treatments to prevent the progression of non alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH) remain unsatisfactory. A total of 56 rabbits were arrayed into 7 groups fed with standard rabbit chow (SRC), SRC with 1% cholesterol, or each of the five experimental treatments (Kampo formulas 1% keishibukuryogan [KBG], 1% orengedokuto [OGT], and 1% shosaikoto [SST]; vitamin E [VE]; or pioglitazone [PG]) in a 1% cholesterol SRC. We analyzed changes after 12 weeks in plasma and liver lipid profiles, glucose metabolism, adipocytokines, oxidative stress, and liver fibrosis. Data demonstrated that all five treatments were associated with significant amelioration of lipid profiles, oxidative stress, and liver fibrosis compared to no supplementation. KBG was superior to VE and PG in the reduction of liver total cholesterol (P < 0.01) and lipid peroxidase levels (P < 0.05), urinary 8-hydroxy-2'-deoxyguanosine (P < 0.05), hepatic alpha-smooth muscle actin positive areas (P < 0.01) and activated stellate cells (P < 0.01). In conclusion, there was a statistically significant benefit of Kampo formulas (KBG in particular) on a dietary model of NAFLD/NASH. Future studies need to be directed at the mechanisms in the treatment of NASH.


Asunto(s)
Modelos Animales de Enfermedad , Medicina Basada en la Evidencia , Hígado Graso/tratamiento farmacológico , Medicina Kampo , Adipoquinas/sangre , Alcoholes , Animales , Biomarcadores , Glucemia/metabolismo , Peso Corporal/efectos de los fármacos , Química Farmacéutica , Hígado Graso/sangre , Hígado Graso/patología , Ácido Hialurónico/sangre , Lípidos/sangre , Cirrosis Hepática/metabolismo , Masculino , Tamaño de los Órganos/efectos de los fármacos , Estrés Oxidativo , Conejos , Factor de Crecimiento Transformador beta1/sangre
15.
J Med Food ; 10(4): 563-5, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18158823

RESUMEN

The epidemic of non-alcoholic fatty liver disease (NAFLD) in the United States is staggering, and there is an enormous void in our understanding of the clinical epidemiology other than the common themes of obesity and insulin resistance. There is also a public health need to better define effective treatments of NAFLD, including dietary interventions and appropriate nutritional supplements. There is, however, a wealth of basic science that helps to set the stage for defining the mechanisms leading to liver pathology. In this article we will attempt to put these concepts in perspective to highlight the need for future research including the use of medicinal food.


Asunto(s)
Dieta , Hígado Graso/epidemiología , Hígado Graso/terapia , Animales , Suplementos Dietéticos , Hígado Graso/etiología , Humanos , Inflamación , Estilo de Vida , Estrés Oxidativo , Estados Unidos/epidemiología , Pérdida de Peso
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA